Skip to content
VectorGene
vi
Nội dung lâm sàng và kỹ thuật được cung cấp bằng tiếng Anh.

CHGB · Partner-reported service scope

VEGF Pan-Cancer Screening

Detection of vascular endothelial growth factor abnormalities across the cancer care continuum: early detection, treatment efficacy evaluation and post-treatment recurrence monitoring.

Method
VEGF detection
Blood sample tubes in a laboratory rack. Illustrative stock photograph.
Blood sample tubes in a laboratory rack

CHGB · Partner-reported

Service capabilities

The following scope is reported by the partner. Quantities describe the partner portfolio and do not represent VectorGene’s own track record.

Early detection
Treatment efficacy evaluation
Recurrence monitoring

Explore the related platform.

Advanced genomic testing platforms for precision oncology, inherited disease analysis, pathogen sequencing, microbiome analysis and population-level genomic programmes.

Genomics & NGS Testing
Varies by jurisdiction

Diagnostic testing is regulated differently in every jurisdiction. VectorGene supports local validation and accreditation; the regulatory dossier remains owned by the local institution.

Explore services in this category.

Read each service’s complete scope and regulatory note. These links help you explore the portfolio; programme-specific suitability requires feasibility assessment.

Review the assay’s claim, population and evidence.

The supplied service title describes the partner’s proposed screening approach. Assess that proposal using evidence for the actual assay and intended population. A biomarker’s biological relevance alone cannot settle the performance or clinical utility of a broad screening programme.

An elevated tumour marker can occur in noncancerous conditions. Marker measurements are commonly interpreted with other investigations; detecting a marker alone does not establish a cancer diagnosis.

NCI: Tumor Markers

NCI explains that the effectiveness of multi-cancer detection tests for screening people without symptoms remains uncertain and requires evaluation in randomised clinical trials.

NCI: Screening Tests

External references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.

Questions for the programme brief

  1. What exactly is claimed?

    Request the analyte, method, decision thresholds, intended population and documented status of the proposed test.

  2. How were results evaluated?

    Review the study design, comparator, false results and whether evidence concerns diagnosis or asymptomatic screening.

  3. Can the institution support follow-up?

    Map confirmatory investigation, clinical review and the treatment of uncertain or conflicting results before evaluating programme scale.

What to prepare for review
  • Assay specification and intended-use statement
  • Study reports supporting each screening claim
  • Local follow-up and governance proposal

Working environments

Laboratory context for biomarker services.

Illustrative stock photography provides context for the people, processes and working environments behind this capability.

Purple pipette and laboratory tubes. Illustrative stock photograph.
Purple pipette and laboratory tubes
A technician in protective clothing working with laboratory instrumentation. Illustrative stock photograph.
Technician working with laboratory instrumentation
Microscope detail on a laboratory bench. Illustrative stock photograph.
Microscope detail on a laboratory bench
Stress fibres and microtubules in breast cancer cells. Illustrative stock photograph.
Stress fibres and microtubules in breast cancer cells

Start a conversation

Discuss VEGF Pan-Cancer Screening

This service will be retained as context for your enquiry. Choose the platform or support area you want to develop at your institution.
Partner with us